[1]贾艳增,马玉兰,陈　莹,等.碳青霉烯耐药高毒力肺炎克雷伯菌的实验室研究及与临床转归相关危险因素分析[J].现代检验医学杂志,2021,36(01):112-115.[doi:10.3969/j.issn.1671-7414.2021.01.028]
　JIA Yan-zeng,MA Yu-lan,CHEN Ying,et al.Laboratory Study and Analysis of Risk Factors Associated with Clinical Ouecomes of Hypervirulent and Carbapenem-resistant Klebsiella Pneumonia[J].Journal of Modern Laboratory Medicine,2021,36(01):112-115.[doi:10.3969/j.issn.1671-7414.2021.01.028]
点击复制

碳青霉烯耐药高毒力肺炎克雷伯菌的实验室研究及与临床转归相关危险因素分析()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年01期
页码:
112-115
栏目:
检验与临床
出版日期:
2021-02-05

文章信息/Info

Title:
Laboratory Study and Analysis of Risk Factors Associated with Clinical Ouecomes of Hypervirulent and Carbapenem-resistant Klebsiella Pneumonia
文章编号:
1671-7414（2021）01-112-04
作者:
贾艳增，马玉兰，陈　莹，等
（1.河北医科大学第二医院检验科，石家庄 050000；2.石家庄第四医院检验科，石家庄 050017）
Author(s):
JIA Yan-zeng, MA Yu-lan, CHEN Ying, et al
(1.Department of Laboratory Medicine ,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China; 2.Department of Laboratory Medicine,the Fourth Hospital of Shijiangzhuang, Shijiazhuang 050017,China)
关键词:
碳青霉烯耐药高毒力肺炎克雷伯菌; 实验室检测; 临床转归
分类号:
R378.996；R446.5
DOI:
10.3969/j.issn.1671-7414.2021.01.028
文献标志码:
A
摘要:
目的　研究碳青霉烯耐药高毒力肺炎克雷伯菌（ hypervirulent and carbapenem-resistant Klebsiella pneumonia， CR-HvKP）实验室检测及临床转归相关危险因素。方法　回顾性研究 2016年 12月～ 2017年 12月河北医科大学第二医院 CR-HvKP感染患者 20例，对患者临床资料进行分析，采用 PCR检测毒力基因 (rmpA和 rmpA2)、血清型（ K1和 K2）以及碳青霉烯酶基因（ KPC-2，NDM-1，OXA，VIM和 IMP）。结果　20例 CR-HvKP感染患者中，毒力基因 rmpA2均为阳性，拉丝试验阳性 17例（85%）,K2血清型 16例（80%）和碳青霉烯酶基因 KPC-2型 18例（90%）。标本来源主要为痰 /肺泡灌洗液 16例（80%），治疗好转 9例 (45%)和治疗无效 11例 (55%)。患者使用气管插管辅助呼吸以及感染并发症危及生命的感染性休克治疗无效和好转比较 ,差异均具有统计学意义 (χ2=5.690～ 7.593,均 P<0.05)。结论　CR-HvKP感染临床治愈率低，传播性强，应引起高度重视。

参考文献/References:

[1] GU Danxia, DONG Ning, ZHENG Zhiwei, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study [J].The Lancet Infectious Diseases, 2018, 18(1):37-46.
[2] ZHOU Yun,WANG Xing,SHEN Jun,et al Endogenous endophthalmitis caused by carbapenem-resistant hypervirulent Klebsiella Pneumoniae: A case report and literature review [J].Ocul Immunol In.amm,2o19,27(7):1099-1104.
[3] MARR C M， RUSSO T A. Hypervirulent Klebsiella pneumoniae: a new public health threat[J]. Expert Review of Anti-infective Therapy ,2018 ,17(2):71-73.
[4] CHOBY J E ,HOWARD-ANDERSON J ,WEISS D S et al. Hypervirulent Klebsiella pneumoniae -clinical and molecular perspectives(Review) [J].Intern Med,2020 ,287(3):283-300.
[5] LI Jiayang, REN Jianan, WANG Gefei, et al. Risk factors and clinical out comes of hypervirulent Klebsiella pneumoniae induced bloodstream infections. [J]. European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37(4):679-689.
[6] ZHAO Yajie，ZHANG Xiucai，TORRES V V L，et al. An outbreak of carbapenem-resistant and hyperviru-lent Klebsiella pneumoniae in an intensive care unit of a Major Teaching Hospital in Wenzhou, China(Article) [J]. Frontiers in Public Health, 2019, 7:229.
[7] SOHEI H，YOHEI D. Hypervirulent Klebsiella pneumoniae: a call for consensus definition and international collaboration [J]. Journal of Clinical Microbiology,2018 ,56(9):e00959-18.
[8] RUSSO TA, MARR C M .Hypervirulent Klebsiella pneu-moniae[J].Clin Microbiol Rev,2019,32(3):e00001-19.
[9] LIU Chao,GUO Jun. Hypervirulent Klebsiella pneumoniae (hypermucoviscous and aerobactin positive) infection over 6 years in the elderly in China: antimicrobial resistance patterns, molecular epidemiology and risk factor [J] .Ann Clin Microbiol Antimicrob,2019,18(1):4.
[10] CATáN-NáJERA J C, GARZA-RAMOS U, BARRIOS-CAMACHO H. Hypervirulence and hypermucoviscosity: Two different but complementary Klebsiella spp. phenotypes [J] .Virulence, 2017, 8(7):1111-1123.
[11] LAM M M C, WYRES K L, DUCHêNE S, et al. Population genomics of hypervirulent Klebsiella pneumoniae clonal-group 23 reveals early emergence and rapid global dissemination[J]. Nat Commun, 2018, 9(1):2703.
[12] ZHAN Lingling, WANG Shanshan, GUO Yinjuan, et al. Outbreak by hypermucoviscous Klebsiella pneumoniae ST11 isolates with carbapenem resistance in a tertiary Hospital in China [J].Front Cell Infect Microbiol , 2017, 7:182.
[13] WONG M H Y, SHUM H P, CHEN J H K, et al .Emer-gence of carbapenem-resistant hypervirulent Klebsiella Pneumoniae[J].Lancet Infect Dis,2018,18(1):24.
[14] LEE C R, LEE J H, PARK K S, et al.Antimicrobial resistance of hypervirulent Klebsiella pneumoniae: epidemiology, hypervirulence-associated determinants and resistance mechanisms[J].Front Cell Infect Microbiol ,2017 ,7:483.
[15] ZHOU Kai, XIAO Tingting, DAVID S,et al. Novel subclone of carbapenem-resistant Klebsiella pneumoniae sequence type 11 with enhanced virulence and transmissibility, China[J].Emerg Infet Dis,2020,26(2):289-297.
[16] DONG Ning,LIN Dachuan,ZHANG Rong,et al. Carriage of blaKPC-2 by a virulence plasmid in hypervirulent Klebsiella pneumoniae [J].Antimicrob Chemother, 2018,73(12):3317-3321.
[17] SIU L K, HUANG D B, CHIANG T. Plasmid transfer-ability of KPC into a virulent K2 serotype Klebsiella pneumoniae [J]. BMC Infect Dis ,2014,14:176.
[18] ZHANG Rong,LIN Dachuan,CHAN E W C,et al. Emergence of carbapenem-resistant serotype k1 hypervirulent Klebsiella pneumoniae strains in China[J].Antimicrob Agents Chemother,2015,60 (1):709-711.
[19] 杜芳玲，龙丹 ,魏丹丹，等 .K1和 K2血清型肺炎克雷伯菌耐药性与可移动遗传元件研究 [J].中华医院感染学杂志，2019,29（8）:1127-1130. DU Fangling,LONG Dan,WEI Dandan, et al. Study on drug resistance and mobile genetic elements of Klebsiella pneumoniae of K1 and K2 serotypes [J].Chinese Journal of Nosocomiology,2019,29（8）:1127-1130.
[20] Clinical and Laboratory Standards Institute. CLSI M100-S2: The performance stands for antimi-crobial susceptibility testing[S].Wayne: PA,CLSI M100-S27,2017.
[21] 李军 , 黄紫嫣 , 谭媛 , 等 .血液分离碳青霉烯类耐药肺炎克雷伯菌耐药机制及同源性研究 [J].中华医院感染学杂志，2019,29（17）:2561-2565,2593. LI Jun, HUANG Ziyan, TAN Yuan, et al. Drug resis-tance mechanisms and homology of carbapenem-resis-tant Klebsiella pneumoniae isolated from blood spec-imens[J]. Chinese Journal of Nosocomiology, 2019, 29(17): 2561-2565,2593.
[22] WU Xiaomai, ZHU Yefei, CHEN Qiuying, et al. Tigecycline therapy for nosocomial pneumonia due to carbapenem-resistant gram-negative bacteria in critically ill patients who received inappropriate initial antibiotic treatment: a retrospective case study[J]. Int,2016,2016:8395268.
[23] MORITZ F, CAN I, SUSANNE H, et al. Treatment options for carbapenem- resistant gram-negative infec-tions [J].Dtsch Arztebl Int.2018 ,115(20-21):345-352.
[24] YANG Ping, CHEN Yunbo, JIANG Saiping, et al. Association between antibiotic consumption and the rate of carbapenem-resistant gram-negative bacteria from China based on 153 tertiary hospitals data in 2014[J].Antimicrob Resist Infect Control, 2018, 7:137.

相似文献/References:

[1]胡天喜,闫　彬,陶林静,等.糖尿病并发新型冠状病毒肺炎患者临床实验室常规检测指标变化及应用价值研究[J].现代检验医学杂志,2022,37(03):132.[doi:10.3969/j.issn.1671-7414.2022.03.028]
　HU Tian-xi,YAN Bin,TAO Lin-jing,et al.Changes and Application Value of Clinical Laboratory Routine Testing Indicators in Patients with Diabetes Mellitus Complicated with Corona Virus Disease 2019[J].Journal of Modern Laboratory Medicine,2022,37(01):132.[doi:10.3969/j.issn.1671-7414.2022.03.028]

备注/Memo

备注/Memo:
基金项目：河北医科大学第二医院科学研究基金资助项目（2h2017036）。
作者简介：贾艳增（1990-），女，硕士研究生，主要从事细菌耐药机制的研究。
通讯作者：时东彦，E-mail:shidongyan73@126.com。
更新日期/Last Update: 2021-02-05